Prescription medicine
Trientine Brand names: Cuvrior, Syprine
Trientine (Cuvrior) is a prescription medicine with an FDA approval on record since 1985. FDA's NDC Directory lists it from 6 generic labelers, and pharmacies paid $2.30 per trientine HCl 250 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the trientine FDA label on DailyMed (effective September 1, 2020, Bausch Health US LLC); the NDA 19194 record on Drugs@FDA; every trientine label on DailyMed.
Highlights of the record
FDA label of September 1, 2020; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageSyprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine.
Forms and strengths
- 250 mg
- 300 mg
- 500 mg
Capsule; film-coated tablet.
On the market
- Earliest approval on file
- November 8, 1985 Syprine, Bausch; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 14 first February 7, 2018; 7 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 8 of which 6 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- May 3, 2039 Cuvrior tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $2.30 per capsule Trientine HCl 250 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 478 through July 30, 2026
What is trientine used for?
From the label: indications and usageSyprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. Syprine should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, Syprine is not recommended in cystinuria or rheumatoid arthritis. […]
FDA pharmacologic class: Copper Chelator and Metal Chelator.
Source: FDA drug label (Syprine), Bausch Health US LLC, effective September 1, 2020 (SPL set c34f77a7-996b-4470-b5df-d946a7fe5dbe), via openFDA; the full label on DailyMed
Is there a generic for trientine (Cuvrior)?
The FDA approved the first generic trientine on February 7, 2018. 14 generic applications are approved; 7 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists trientine from 6 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 5 patents for Cuvrior tablets: the compound patent runs to May 3, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1985 earliest approval on file
- 2018 first generic approved
- 2039 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for trientine (Cuvrior)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.30 per Trientine HCl 250 mg capsule, down 46% from $4.30 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Trientine HCl 250 mg capsule (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Trientine HCl 250 mg capsule | Generic | $2.30 per capsule | $69.08 | -46% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for trientine?
The FDA Adverse Event Reporting System holds 478 reports that list trientine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 28 are coded as a death and 93 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Trientine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other